A citation-based method for searching scientific literature

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin-Haeng Chung, Yoon La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M Ali, Myung-Ju Ahn, Byoung Chul Cho. J Clin Oncol 2017
Times Cited: 183



A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari, S C Wang, K D Wilner, J W Clark, S-H I Ou. Ann Oncol 2019
Times Cited: 144




List of shared articles



Times cited

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
B W Carter, M Altan, G S Shroff, M T Truong, I Vlahos. Clin Radiol 2022
1

Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.
Joel Rivera-Concepcion, Dipesh Uprety, Alex A Adjei. Cancer Res Treat 2022
0

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
1

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Luis Paz-Ares, Adam Gondos, Diego Saldana, Marlene Thomas, Celine Mascaux, Lukas Bubendorf, Fabrice Barlesi. Lung Cancer 2022
1

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0


Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
12

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022
0

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.
Maria Saigí, Enric Carcereny, Teresa Morán, Marc Cucurull, Marta Domènech, Ainhoa Hernandez, Anna Martinez-Cardús, Eva Pros, Montse Sanchez-Cespedes. Cancer Treat Rev 2022
0

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
43


Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
24


Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
2

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
12

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
8

Lung Cancer Stem Cells-Origin, Diagnostic Techniques and Perspective for Therapies.
Agata Raniszewska, Iwona Kwiecień, Elżbieta Rutkowska, Piotr Rzepecki, Joanna Domagała-Kulawik. Cancers (Basel) 2021
4

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów, Piotr Dzięgiel. Cancers (Basel) 2021
14


Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
3

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
163

Twenty-five years of Respirology: Advances in lung cancer.
Mei-Kim Ang, Tony S K Mok. Respirology 2020
2

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.
Anurag Mehta, Mumtaz Saifi, Ullas Batra, M Suryavanshi, Kush Gupta. Lung Cancer (Auckl) 2020
3

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
30

Emerging therapeutic agents for advanced non-small cell lung cancer.
Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou, Yanyan Lou. J Hematol Oncol 2020
51

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Swapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, Benjamin Leach, TingTing Tan, Prakash Kulkarni, Ravi Salgia. J Clin Med 2020
9

Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
Karen L Reckamp, Tejas Patil, Kedar Kirtane, Thereasa A Rich, Carin R Espenschied, Caroline M Weipert, Victoria M Raymond, Rafael Santana-Davila, Robert C Doebele, Christina S Baik. Clin Lung Cancer 2020
4

Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Expert Opin Pharmacother 2020
4

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
10

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.
Jessica J Lin, Adam Langenbucher, Pranav Gupta, Satoshi Yoda, Isobel J Fetter, Marguerite Rooney, Andrew Do, Marina Kem, Kylie Prutisto Chang, Audris Y Oh,[...]. NPJ Precis Oncol 2020
12

Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
Boris Sepesi, Tina Cascone, Stephen G Chun, Mehmet Altan, Xiuning Le. Surg Oncol Clin N Am 2020
4

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
15

Update 2020: Management of Non-Small Cell Lung Cancer.
Mariam Alexander, So Yeon Kim, Haiying Cheng. Lung 2020
40

Tyrosine Kinase Receptors in Oncology.
Jorge Esteban-Villarrubia, Juan José Soto-Castillo, Javier Pozas, María San Román-Gil, Inmaculada Orejana-Martín, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso-Gordoa, Javier Molina-Cerrillo. Int J Mol Sci 2020
13

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
5

How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Lorenza Landi, Federico Cappuzzo. Transl Lung Cancer Res 2020
3